AND -Service Agreement • March 14th, 2003 • Oxford Glycosciences PLC /Ny • Biological products, (no disgnostic substances) • England
INDEXOxford Glycosciences PLC /Ny • March 14th, 2003 • Biological products, (no disgnostic substances)
AND -Employment Agreement • March 14th, 2003 • Oxford Glycosciences PLC /Ny • Biological products, (no disgnostic substances) • England
EXHIBIT 23 [LETTERHEAD OF OXFORD GLYCOSCIENCES (UK) LTD] 30 September 2002 Dr Chris Moyses The Old Barn Great Milton Oxfordshire 0X44 7NF Dear Chris Amendment to Employment Agreement I refer to the Employment Agreement dated 5 June 1998 between Oxford...Employment Agreement • March 14th, 2003 • Oxford Glycosciences PLC /Ny • Biological products, (no disgnostic substances)
Company Oxford Glycosciences PLC TIDMOGS Headline Re Agreement Released 07:01 19 Sep 2002 Number 3693B For further information please contact: Oxford GlycoSciences Plc David Ebsworth, Chief Executive Officer Website: www.ogs.com Tel: +44 (0) 1235...Oxford Glycosciences PLC /Ny • October 1st, 2002 • Biological products, (no disgnostic substances)
Oxford, UK, 19 September 2002 -- Oxford GlycoSciences Plc (LSE: OGS, Nasdaq: OGSI) today announced that it has entered a Cooperative Research and Development Agreement (CRADA) with the Center for Drug Evaluation and Research of the US Food and Drug Administration (FDA). The research collaboration will aim to identify serum protein biomarkers that could be useful across species during drug development for early prediction and evaluation of drug‑induced toxicities to minimize risk of serious adverse events in clinical trials as well as after drug approval.
